Fragment-based drug discovery (FBDD) has been successfully applied to develop novel and selective compounds, including kinase inhibitors. Fragments are low molecular weight compounds targeting a specific subpocket within the active site of a protein. They usually bind to their target with weaker activity than traditional drug-like molecules but with a good binding efficiency, i.e. a higher proportion of the atoms is interacting with the protein. In drug design, molecules can be viewed as combinations of multiple fragments. Linking, replacing, or recombining fragments is the essence of FBDD. Fragments can be generated computationally by decomposing larger compounds. Clearly, the choice of the fragmentation technique will have an impact on the resulting fragment library. For example, RECAP (REtrosynthetic Combinatorial Analysis Procedure) and BRICS (Breaking of Retrosynthetically Interesting Chemical Substructures) aim to cut only synthetically meaningful chemical bonds. eMolFrag builds on top of BRICS to generate a set of (larger) bricks and (smaller) connecting linkers.